DiaMedica Therapeutics (NASDAQ:DMAC) Given New $11.00 Price Target at Craig Hallum

DiaMedica Therapeutics (NASDAQ:DMAC - Free Report) had its price objective raised by Craig Hallum from $8.00 to $11.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright increased their target price on DiaMedica Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday.

DiaMedica Therapeutics Stock Up 11.5%

Shares of DMAC stock traded up $0.48 on Friday, hitting $4.66. The company had a trading volume of 473,397 shares, compared to its average volume of 112,747. The firm has a market cap of $199.78 million, a P/E ratio of -7.30 and a beta of 1.17. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $6.82. The company has a 50-day moving average price of $3.93 and a 200-day moving average price of $4.68.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.18). During the same period last year, the firm posted ($0.14) earnings per share. Equities research analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Large investors have recently made changes to their positions in the stock. Perigon Wealth Management LLC purchased a new position in DiaMedica Therapeutics in the second quarter worth approximately $207,000. Goldman Sachs Group Inc. grew its position in DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company's stock worth $462,000 after acquiring an additional 52,854 shares during the period. Jane Street Group LLC grew its position in DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock worth $382,000 after acquiring an additional 58,457 shares during the period. Royal Bank of Canada grew its position in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock worth $588,000 after acquiring an additional 154,701 shares during the period. Finally, World Investment Advisors grew its position in DiaMedica Therapeutics by 17.0% in the first quarter. World Investment Advisors now owns 25,650 shares of the company's stock worth $97,000 after acquiring an additional 3,735 shares during the period. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.